A Phase 1/2 Study to Evaluate OTX-2002 in Patients With Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association With the MYC Oncogene

A Phase 1/2 Study to Evaluate OTX-2002 in Patients With Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association With the MYC Oncogene
Conditions:   Hepatocellular Carcinoma;   Solid Tumor;   Hepatocellular Carcinoma Non-resectable;   Hepatocellular Carcinoma Recurrent;   Hepatocellular Cancer;   Liver Cancer;   Liver, Cancer of, Non-Resectable
Interventions:   Drug: OTX-2002;   Drug: Tyrosine kinase inhibitor One;   Drug: Tyrosine kinase inhibitor Two;   Drug: Checkpoint Inhibitor, Immune
Sponsor:   Omega Therapeutics
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 25, 2022Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments